This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01228669
First received: October 25, 2010
Last updated: February 9, 2017
Last verified: February 2017
  Purpose
This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the safety, pharmacokinetics (how the trial drug is distributed in the body) and pharmacodynamics (physiological effects of the drug on the body) of NNC 0172-0000-2021 administered intravenously and subcutaneously to healthy male subjects and subjects with haemophilia A or B

Condition Intervention Phase
Congenital Bleeding Disorder Haemophilia A Haemophilia B Healthy Drug: NNC 0172-0000-2021 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Number of adverse Events (AEs), including Serious Adverse Events (SAEs) [ Time Frame: from trial product administration until 43 days after trial product administration ]

Secondary Outcome Measures:
  • Area under the concentration-time curve [ Time Frame: from 43 days after trial product administration until 53 days after trial product administration ]
  • Adverse Events (AEs), including Serious Adverse Events (SAEs) [ Time Frame: from 43 days after trial product administration until 53 days after trial product administration ]

Enrollment: 52
Study Start Date: October 2010
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NNC 0172-0000-2021
Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
Experimental: B Drug: NNC 0172-0000-2021
Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
Placebo Comparator: C Drug: placebo
Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight between 50 and 100 kg, both inclusive
  • Body mass index (BMI) between 18.0 kg/m2 and 25.0 kg/m2, both inclusive
  • For haemophilia subjects only: Diagnosed with severe haemophilia A or B

Exclusion Criteria:

  • Known or suspected hypersensitivity to trial product(s) or related products
  • Surgery planned to occur during the trial
  • Any major and/or orthopaedic surgery within 30 days prior to trial product administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01228669

Locations
Austria
Novo Nordisk Investigational Site
Wien, Austria, 1090
Denmark
Novo Nordisk Investigational Site
København, Denmark, 2100
Germany
Novo Nordisk Investigational Site
Berlin, Germany, 10249
Novo Nordisk Investigational Site
Frankfurt/M., Germany, 60590
Italy
Novo Nordisk Investigational Site
Milano, Italy, 20124
Malaysia
Novo Nordisk Investigational Site
Kuala Lumpur, Malaysia, 50400
South Africa
Novo Nordisk Investigational Site
Parktown Johannesburg, Gauteng, South Africa, 2193
Spain
Novo Nordisk Investigational Site
Madrid, Spain, 28046
Sweden
Novo Nordisk Investigational Site
Malmö, Sweden, 214 28
Switzerland
Novo Nordisk Investigational Site
Zürich, Switzerland, 8091
Thailand
Novo Nordisk Investigational Site
Bangkok, Thailand, 10400
United Kingdom
Novo Nordisk Investigational Site
Harrow, United Kingdom, HA1 3UJ
Novo Nordisk Investigational Site
London, United Kingdom, NW3 2QG
Novo Nordisk Investigational Site
London, United Kingdom, SE1 7EH
Novo Nordisk Investigational Site
London, United Kingdom, W12 0NN
Novo Nordisk Investigational Site
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Publications:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01228669     History of Changes
Other Study ID Numbers: NN7415-3813
2010-020465-24 ( EudraCT Number )
U1111-1116-2356 ( Other Identifier: WHO )
Study First Received: October 25, 2010
Last Updated: February 9, 2017

Additional relevant MeSH terms:
Hemophilia A
Hemophilia B
Blood Coagulation Disorders
Hemostatic Disorders
Blood Coagulation Disorders, Inherited
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 21, 2017